Literature DB >> 8179595

PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment.

M R Soma1, R Baetta, S Bergamaschi, M R De Renzis, C Davegna, F Battaini, R Fumagalli, S Govoni.   

Abstract

The parallel effects of simvastatin on cell cycle and PKC activity in rat C6 glioma cells were investigated. Simvastatin, 2.5 microM, for 24 h resulted in cell growth arrest in early G1 phase of the cell cycle and in a significant increase of total PKC activity (283 +/- 42 vs 470 +/- 61 pmoles/min/mg protein p = 0.002 for control cells and simvastatin-treated cells, respectively). The effect of simvastatin was fully prevented by mevalonate. A time dependent increase of PKC activity was observed in control exponentially free-growing C6 cells approaching confluency: a highly significant negative correlation (r = -0.91 p < 0.0001) between PKC activity and growth rate was calculated. PKC activity was high in cells arrested in G0 by serum starvation (0.4%). Following addition of complete medium (17.5% serum) the PKC activity progressively decreased and reached a minimum when cells traversed the G2/M phase, as determined by DNA analysis distribution. PKC activity dropped 30% in simvastatin-arrested early G1 cells; 44% in hydroxyurea-arrested cells at the G1/S boundary; and 73% in Colcemid mitosis-blocked cells. The results show that C6 glioma cell PKC activity is maximal in a G0 quiescent state and varies at different points of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8179595     DOI: 10.1006/bbrc.1994.1570

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Activation of extracellular signal-regulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1.

Authors:  S Dangi; F M Chen; P Shapiro
Journal:  Cell Prolif       Date:  2006-08       Impact factor: 6.831

Review 2.  The role of statins in neurosurgery.

Authors:  Jorge Humberto Tapia-Pérez; Martin Sanchez-Aguilar; Thomas Schneider
Journal:  Neurosurg Rev       Date:  2010-04-29       Impact factor: 3.042

3.  Effects of interferon and PKC modulators on human glioma protein kinase C, cell proliferation, and cell cycle.

Authors:  M Acevedo-Duncan; R Zhang; D R Cooper; H M Greenberg
Journal:  Neurochem Res       Date:  1997-07       Impact factor: 3.996

4.  Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: correlation with culture confluency, cell cycle phase and serum response.

Authors:  P J Nelson; I H Gelman
Journal:  Mol Cell Biochem       Date:  1997-10       Impact factor: 3.396

5.  Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature.

Authors:  Luis F Rendon; Ishaan A Tewarie; David J Cote; Aaron Gabriel; Timothy R Smith; Marike L D Broekman; Rania A Mekary
Journal:  Drugs       Date:  2022-02-05       Impact factor: 9.546

6.  Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin.

Authors:  Jan Gliemroth; Henryk Zulewski; Hans Arnold; A Jorge A Terzis
Journal:  Neurosurg Rev       Date:  2003-05       Impact factor: 3.042

7.  Modulation by simvastatin of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine coronary artery smooth muscle cells.

Authors:  S W Seto; A L S Au; T Y Lam; S S C Chim; S M Y Lee; S Wan; D C S Tjiu; N Shigemura; A P C Yim; S W Chan; S K W Tsui; G P H Leung; Y W Kwan
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

8.  Use of statins or NSAIDs and survival of patients with high-grade glioma.

Authors:  Corinna Seliger; Julia Schaertl; Michael Gerken; Christian Luber; Martin Proescholdt; Markus J Riemenschneider; Michael F Leitzmann; Peter Hau; Monika Klinkhammer-Schalke
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

9.  Use of statins and risk of glioma: a nationwide case-control study in Denmark.

Authors:  D Gaist; L Andersen; J Hallas; H Toft Sørensen; H D Schrøder; S Friis
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.